

Press Release

Opto Circuits' subsidiary, Eurocor's partner, Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent

Bonn, Germany | Bengaluru, India | August 2, 2011

Opto Circuits (I) Ltd.'s wholly-owned subsidiary Eurocor GmbH is pleased to announce that their partner Micell Technologies has completed patient enrollment in its DESSOLVE II CE Mark clinical study of the MiStent® Drug-Eluting Coronary Stent System. The MiStent® DES is an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. Enrollment of 183 patients across 26 study centers throughout Europe and New Zealand was accomplished ahead of schedule.

Micell previously announced that, based on results observed in the DESSOLVE I first-in-human trial, the sample size in the DESSOLVE II CE Mark study was reduced from 270 to 171 subjects.

"We believe that by exceeding the projected enrollment rate for this study and completing enrollment in just 5 months, participating clinicians have demonstrated their enthusiasm for the novel MiStent drug-eluting stent," commented Dennis J. Donohoe, M.D., Micell's Chief Medical Advisor.

The MiStent® DES employs Micell's proprietary and patented supercritical fluid technology which applies a precisely controlled absorbable polymer - active drug (sirolimus) matrix onto Eurocor's leading [Genius® Magic Cobalt Chromium Bare Metal](#) (BMS) stent system. The polymer dissolves and releases the drug into the surrounding tissue in a controlled manner, designed to optimize dosing of the drug throughout the effected artery. In GLP preclinical trials, the drug and the polymer are cleared from the stent within 45 to 60 days *in vivo*, resulting in a bare-metal stent.

The DESSOLVE II CE Mark trial is a multi-center study of patients with documented stable or unstable angina pectoris. The primary endpoint is superiority of the MiStent® DES in minimizing in-stent late lumen loss at nine months, compared to Medtronic's Endeavor® Sprint DES, as measured by the angiography core laboratory in *de novo* lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 30 mm length stent.

More information on the DESSOLVE II trial can be found at www.ClinicalTrials.gov.

In 2009, Maxcor Lifescience, Inc., a subsidiary of Opto Circuits (I) Ltd entered into a strategic cooperation agreement with Micell Technologies for developing and commercializing leading edge Rapamycin (Sirolimus) - based drug-eluting stents (DES) and drug-eluting balloons (DEB).

About: Micell Technologies Inc.

Micell Technologies is a biomedical company that is enhancing the performance of medical devices with innovative drug-delivery systems. Its unique surface and polymer modification technologies enable Micell to precisely and consistently control drug elution and polymer exposure duration, creating the potential for a therapeutic solution to coronary artery disease without the long-term safety concerns of currently available drug-eluting stents. Micell is also developing a drug-coated balloon for vascular interventions. Visit us at www.micell.com.

Micell Technologies, Inc: 801 Capitola Drive, Suite 1, Durham, NC 27713-4384

Eurocor GmbH: In den Dauen, 6a - 53117 Bonn, Germany

Opto Circuits (India) Ltd.: # 83, Electronics City, Bengaluru - 560 100, Karnataka, India

The MiStent Drug Eluting Coronary Stent System is an investigational device. It is not yet approved or available for sale in any market.

Micell, Micell Technologies, the Micell Logo, and MiStent DES are among the registered trademarks of Micell Technologies, Inc.

About: Eurocor GmbH

Eurocor GmbH is a rapidly growing European Life Sciences Technology corporation specialising in the research, development and manufacture of interventional cardiology products. Eurocor is providing interventional cardiologists with innovative, coronary stent technologies and special cardiovascular devices.

The products manufactured by the company in Bonn are used in minimally invasive cardiovascular and peripheral surgery and comply with biological and biomechanical principles to offer highly flexible, adaptable solutions. Strong research and development, close collaboration with clinicians, outstanding quality standard philosophy and global scientific alliances lead to optimisation of clinically effective technologies. For more information, please visit www.eurocor.de. Follow us on http://twitter.com/Eurocor_Germany

About: Opto Circuits (India) Limited

Headquarters: Bengaluru, Karnataka, India
BSE: 532391 | NSE: OPTOCIRCU
Website: www.optoindia.com

Opto Circuits (India) Ltd. (OCI) is an MNC in the business of design, development, manufacture and marketing of healthcare equipment and medical interventional products. The product profile includes USFDA-listed, CE-marked cardiac and vital signs monitoring systems, anesthesia and respiratory care equipment, automated external defibrillators, stents, catheters, body implants and consumables. Some of OCI's well-known brands are [Cardiac Science](#), [Criticare](#), [Eurocor](#), [Ormed](#), [Mediaid](#) and [Unetixs](#). The company's key markets are North America, Europe and BRIC countries.

Contact

Opto Circuits (India) Ltd.
E: Media - media@optoindia.com;
Investors - ir@optoindia.com
T: +91 80 2852 8088

Adfactors PR
Shrinkhala Varma
E: shrinkhala.varma@adfactorspr.com
T: +91 22 2281 3565